Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms

  • Torrens, Gabriel
  • Cabot, Gabriel|||0000-0002-6452-9945
  • Ocampo-Sosa, Alain A.|||0000-0002-9104-3115
  • Conejo, M. Carmen
  • Zamorano, Laura
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Martínez-Martínez, Luis
  • Oliver, Antonio|||0000-0001-9327-1894
The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.